In plain language
Tesofensine is an experimental small-molecule drug (not a peptide) that affects brain chemicals to reduce appetite. It was originally studied for neurological conditions, then for obesity, where mid-stage human trials reported weight loss. It is not FDA-approved, and its long-term safety, including cardiovascular and psychiatric effects, is not established.
What it is explored for
Tesofensine takes a brain-chemistry approach to appetite, acting on three neurotransmitter systems at once, and a mid-stage obesity trial reported notable weight loss. It is an intriguing candidate, though development has been limited and there are real questions about cardiovascular and mood effects, so the evidence stays mixed and it is not approved. Here is where it has been studied.
- Weight management and appetite support
- Reduced food intake
- Central appetite-pathway research
- Obesity research in clinical trials
These are areas of active interest and reported use, not proven outcomes. This peptide carries a moderate (human) rating, see the evidence summary below for how strong the science actually is.
How it works
Tesofensine is a small molecule that inhibits the reuptake of three brain neurotransmitters: noradrenaline, dopamine, and serotonin.
- Monoamine reuptake inhibition. By increasing noradrenaline, dopamine, and serotonin signaling, it is thought to suppress appetite.
- Central appetite effects. The combined neurotransmitter effects are proposed to reduce food intake and support weight loss.
The mechanism is inferred from pharmacology and mid-stage human trials. Long-term effects, including on mood and the cardiovascular system, are not established.
Evidence summary
Tesofensine has moderate but mixed human evidence. A phase 2 obesity trial reported notable weight loss, but development has been limited and there are concerns about cardiovascular and psychiatric effects at higher doses. It is not approved for weight management.
Reported safety & side effects
Reported effects in trials include increased heart rate and blood pressure, dry mouth, insomnia, and mood changes, which raise safety considerations. Its full long-term safety profile is not established, and it is not an approved medicine.
Frequently asked
Is tesofensine a peptide?
No. Tesofensine is a small-molecule drug that affects brain neurotransmitters, not a peptide. It is included here because it is studied as a weight-loss agent.
Is it approved?
No. Tesofensine is not FDA-approved for weight management or any other indication.
What are the main safety concerns?
Trials have noted increases in heart rate and blood pressure and effects on mood and sleep, which are important safety considerations. Its long-term safety is not established.